MSB

JPMorgan Chase and affiliates have fully exited their substantial holding in Mesoblast, reducing position from ~69.9m to below the 5% threshold via a combination of securities lending unwinding, principal trading, and collateral adjustments completed 17 July 2026. This wholesale institutional exit, executed at modest A$1.89–2.01 prices, indicators diminished confidence or completion of an investment thesis rather than a clinical or commercial setback.

MSB has enrolled the full 300-patient cohort for its pivotal Phase 3 CLBP trial (rexlemestrocel-L), confirming the trial is adequately powered to replicate prior Phase 3 endpoint success; FDA RMAT designation and priority-review eligibility position the program for accelerated approval pathway if efficacy holds.

JPMorgan Chase crossed the 5% threshold in Mesoblast through a multi-entity structure dominated by securities lending (51.2M shares on loan) and asset management operations, signaling institutional confidence in the regenerative medicine player. The holding is primarily derivative (lending/client assets) rather than outright proprietary accumulation, limiting inference about bullish conviction.

JPMorgan Chase exited its substantial holding in Mesoblast (MSB) on 24 June 2026, with the exit achieved through unwinding of securities lending arrangements and modest trading around A$1.95–A$2.00. The move appears administrative (securities-lending collateral return) rather than a loss-of-confidence indicator, though the timing and mechanism warrant monitoring for any underlying clinical or commercial headwinds.